Document Detail


Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.
MedLine Citation:
PMID:  20102918     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Currently, no consensus has been reached regarding the management of hyperlipidemia in patients who develop statin-associated myalgia (SAM). Many statin-intolerant patients use alternative lipid-lowering therapies, including red yeast rice. The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia. The study was conducted in a community-based setting in Philadelphia, Pennsylvania. A total of 43 adults with dyslipidemia and a history of statin discontinuation because of myalgia were randomly assigned to red yeast rice 2,400 mg twice daily or pravastatin 20 mg twice daily for 12 weeks. All subjects were concomitantly enrolled in a 12-week therapeutic lifestyle change program. The primary outcomes included the incidence of treatment discontinuation because of myalgia and a daily pain severity score. The secondary outcomes were muscle strength and plasma lipids. The incidence of withdrawal from medication owing to myalgia was 5% (1 of 21) in the red yeast rice group and 9% (2 of 22) in the pravastatin group (p = 0.99). The mean pain severity did not differ significantly between the 2 groups. No difference was found in muscle strength between the 2 groups at week 4 (p = 0.61), week 8 (p = 0.81), or week 12 (p = 0.82). The low-density lipoprotein cholesterol level decreased 30% in the red yeast rice group and 27% in the pravastatin group. In conclusion, red yeast rice was tolerated as well as pravastatin and achieved a comparable reduction of low-density lipoprotein cholesterol in a population previously intolerant to statins.
Authors:
Steven C Halbert; Benjamin French; Ram Y Gordon; John T Farrar; Kathryn Schmitz; Patti B Morris; Paul D Thompson; Daniel J Rader; David J Becker
Related Documents :
21565858 - Histopathological alterations of the parathyroid glands in haemodialysis patients with ...
3044508 - Combination treatment with cholestyramine and bezafibrate for heterozygous familial hyp...
19917888 - Effects of statin therapy according to plasma high-sensitivity c-reactive protein conce...
22693418 - Repeatability and interobserver reproducibility of artemis-2 high-frequency ultrasound ...
9892588 - Doppler-derived mitral deceleration time: an early strong predictor of left ventricular...
23662098 - Efficacy and tolerability of peginterferon α -2a and peginterferon α -2b, both plus rib...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2009-11-26
Journal Detail:
Title:  The American journal of cardiology     Volume:  105     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-01-27     Completed Date:  2010-02-25     Revised Date:  2010-05-10    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  198-204     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Affiliation:
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Biological Products / administration & dosage,  adverse effects*
Cholesterol, LDL / blood
Drug Administration Schedule
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage,  adverse effects*
Hyperlipidemias / blood,  complications,  drug therapy*
Incidence
Life Style
Male
Middle Aged
Muscle Strength
Muscular Diseases / chemically induced*,  epidemiology
Pravastatin / administration & dosage,  adverse effects*
Recurrence
Treatment Outcome
Grant Support
ID/Acronym/Agency:
T32AG000253/AG/NIA NIH HHS; T32AT000600/AT/NCCAM NIH HHS
Chemical
Reg. No./Substance:
0/Biological Products; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/red yeast rice; 81093-37-0/Pravastatin
Comments/Corrections
Comment In:
Am J Cardiol. 2010 May 15;105(10):1504   [PMID:  20451704 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sexual activity, erectile dysfunction, and incident cardiovascular events.
Next Document:  Do differences in subclinical cardiovascular disease in mexican americans versus European americans ...